Abstract
BackgroundRP1 is an HSV-1-based oncolytic immunotherapy expressing GM-CSF and the fusogenic GALV-GP-R- protein. We present biodistribution and shedding data from 87 patients enrolled in the phase 1 dose expansion (n=14)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
